@PalatinTech

We discover and develop novel therapeutics for patients living with inflammatory and autoimmune conditions. $PTN

 Cranbury, NJ
palatin.com/
Joined February 2013
  • Tweets149
  • Following118
  • Followers883
28Media
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
315
Palatin to Begin Trading on Nasdaq Stock Exchange Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
3
1
6
917
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
629
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
4
492
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
1
1
2
543
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters’ Over-Allotment Option Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
442
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
310
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
1
263
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
1
5
443
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases Read the Full Press Release 👉 palatin.com/press_releases/b… #PTN #PTNT #NYSE #OTCQB #News
8
400
Palatin Announces 1-for-50 Reverse Stock Split Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
301
🚨 Breaking News 🚨: FDA confirms the acceptability of Palatin's Phase 3 trials for PL9643 in Dry Eye Disease! 🌟 Strong tolerability & safety profile. A major step forward in eye care innovation. Learn more: tinyurl.com/PalatinTech #DryEyeDisease #ClinicalTrials #Biotech
2
7
1,080
💡 Rapid & effective symptom relief for Dry Eye Disease is on the horizon! PL9643 is advancing through Phase 3 trials, bringing us closer to a new therapeutic option. Stay informed: tinyurl.com/PalatinTech #EyeCare #Innovation #PalatinTech #DED
1
993
🚀 Palatin Technologies kicks off a Phase 2 obesity study w/ Bremelanotide & Tirzepatide. Learn more: palatin.com/press_releases/f…
1
2
849
This study aims to advance obesity treatment by combining our MCR4 agonists with incretin therapeutics. #ObesityTreatment #ClinicalTrials #Biotech #HealthcareInnovation
1
753
🔥 Breaking: Palatin Technologies $PTN reveals positive results from our Phase 3 trial of PL9643 for Dry Eye Disease at ASCRS 2024! 🌐 Quick relief & excellent safety. Dive into the future of eye care with us! 🚀 #EyeHealth #Biotech palatin.com/press_releases/p…
763
$PTN Vyleesi® (bremelanotide injection) delivers its 7th consecutive quarter of double-digit growth in product revenue and prescriptions dispensed. Prescriptions grew 18% & net product revenue increased 14% over the prior quarter.  bit.ly/3ScqRe9
1,229
With the increased use of FDA-approved GLP-1 agonists for treating obesity, there is an unmet need for treatments with alternative mechanisms of action that will help obese patients meet and maintain their weight loss objectives.
1
651
We believe the MC4R agonist is the best validated mechanism for adjunctive therapy with GLP-1 agonists and weight loss maintenance. Read the full PR announcement bit.ly/46Yr4FA
506
$PTNachieves complete enrollment in Palatin's Phase 3 MELODY-1 study of PL9643 for the treatment of patients with dry eye disease. Topline data is currently expected late 4Q calendar 2023. Interim analysis of the first 120 patients demonstrated:
1
1
459
Excellent safety and tolerability product profile. Potential for PL9643 to address multiple signs and symptoms of dry eye disease. Learn More: bit.ly/3LluOsv
1
346
Load more